1. Volume 141, Issue 1, Pages 2-9 (April 2016)
Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers 
Lorna Rodriguez-Rodriguez, Kim M. Hirshfield, Veronica Rojas, Robert S. DiPaola, Darlene Gibbon, Mira Hellmann, Sara Isani, Aliza Leiser, Gregory M. Riedlinger, Allison Wagreich, Siraj M. Ali, Julia A. Elvin, Vincent A. Miller, Shridar Ganesan 
Gynecologic Oncology 
Volume 141, Issue 1, Pages 2-9 (April 2016)
DOI: /j.ygyno
Copyright © 2017 The Authors Terms and Conditions

2. Fig. 1 Flow diagram representing patient selection.
Gynecologic Oncology  , 2-9DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

3. Fig. 2
Tumor histological subtypes and genes most commonly altered, as evaluated by the MTB.
A. Distribution of ovarian tumor histological subtypes (pie chart) and the count of the genes with alterations that were observed in at least four patients plus CDKN2A and CDKN2B in tumor specimens of ovarian cancer (n=36) (bar graph). B. Distribution of uterine cancer histological subtypes (pie chart) and the count of the genes with alterations that were observed in at least five patients in tumor specimens of uterine cancer (n=25) (bar graph).
Gynecologic Oncology  , 2-9DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions

4. Fig. 3
Progression-free survival on last therapy prior to and immediately following implementation of MTB-based therapy.
Day 0 represents the date of initiation of an MTB-based therapy; PFS=the duration (in days) from the initiation of an MTB-based therapy to patient progression or lack of clinical benefit; purple bar=an MTB-based therapy was the same as the prior therapy; two patients were excluded because they did not receive therapy. Arrows indicate ongoing PFS on MTB-based therapies. Data was last monitored for this paper on September 4, The designation of “ongoing” (represented by arrows) is based on the patient's last physician visit or the patient's status as of September 4, 2015.
Gynecologic Oncology  , 2-9DOI: ( /j.ygyno )
Copyright © 2017 The Authors Terms and Conditions